ClinicalTrials.gg

Program

mRNA-based T-cell Engager mRNA-2808

Its studies are mostly in Multiple Myeloma, led by Moderna.

Furthest: phase 2, since Aug 7, 20251 company-led study, 1 open or runningNext primary completion: Jun 17, 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moderna11 open or runningphase 2since Aug 7, 2025Aug 7, 2025Jun 17, 2030phase 2 · NCT07116616

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2025First study: phase 2 study in RecurrenceFirst studyNCT07116616 · 190 planned · United States

Ahead

  1. Jun 17, 2030Primary completion: phase 2 study in RecurrenceNCT07116616

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07116616Recurrence · United States2RecruitingJun 17, 2030190

How it is read

Names in the registry

  • “mRNA-2808”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.